Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Rev Esp Med Nucl Imagen Mol ; 35(2): 81-7, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26521995

RESUMO

PURPOSE: To explore the relation between tumor kinetic assessed by (18)F-FDG PET and final neoadjuvant chemotherapy (NC) response within a molecular phenotype perspective. MATERIAL AND METHODS: Prospective study included 144 women with breast cancer. All patients underwent a dual-time point (18)F-FDG PET/CT previous to NC. The retention index (RI), between SUV-1 and SUV-2 was calculated. Molecular subtypes were re-grouped in low, intermediate and high-risk biological phenotypes. After NC, all residual primary tumor specimens were histopathologically classified in tumor regression grades (TRG) and response groups. The relation between SUV-1, SUV-2 and RI with the TRG and response groups was evaluated in all molecular subtypes and in accordance with the risk categories. RESULTS: Responder's lesions showed significant greater SUVmax compared to non-responders. The RI value did not show any significant relation with response. Attending to molecular phenotypes, statistical differences were observed with greater SUV for responders having high-risk molecular subtypes. CONCLUSION: Glycolytic tumor characteristics showed a significant correlation with NC response and dependence of risk phenotype.


Assuntos
Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/tratamento farmacológico , Terapia Neoadjuvante , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Biomarcadores , Neoplasias da Mama/genética , Feminino , Humanos , Fenótipo , Estudos Prospectivos
2.
Rev Esp Med Nucl Imagen Mol ; 31(6): 308-14, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23084013

RESUMO

AIM: To analyse the correlation between (18)F-FDG uptake assessed by PET/CT in locally advanced breast tumours and histopathological and immunohistochemical prognostic factors. MATERIAL AND METHODS: Thirty-six women with breast cancer were prospectively evaluated. PET/CT was requested in the initial staging previous to adjuvant chemotherapy (multicentric study). All the patients underwent an (18)F-FDG PET/CT with a dual-time-point acquisition. Both examinations were evaluated qualitatively and semiquantitatively with calculation of SUVmax values in PET-1 (SUV-1) and in PET-2 (SUV-2) and the percentage variation of the standard uptake values (retention index) between PET-1 and PET-2. Clinical and metabolic stages were assessed according to TNM classification. The biological prognostic parameters, such as the steroid receptor status, p53 and c-erbB-2 expression, proliferation rate (Ki-67), and grading were determined from tissue of the primary tumour. Metabolic and biological parameters were correlated. RESULTS: A positive relationship was found between semiquantitative metabolic parameters and biological parameters. SUV-1 and SUV-2 values did not show significant statistical correlation (p<.05) except for the clinical tumour size. About the biological parameters, retention index showed the best results with positive and significant relation (p<.05) with estrogen and progesterone receptor status and Ki-67. Isolated SUV values did not show significant relation to these parameters. CONCLUSION: Retention index showed the best relation with biological parameters compared to isolated SUVmax values. These data suggest that SUV change over time is a prognostic marker.


Assuntos
Neoplasias da Mama/diagnóstico por imagem , Carcinoma Ductal de Mama/diagnóstico por imagem , Radioisótopos de Flúor , Fluordesoxiglucose F18 , Imagem Multimodal , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X , Adulto , Biomarcadores Tumorais/análise , Neoplasias da Mama/química , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Carcinoma Ductal de Mama/química , Carcinoma Ductal de Mama/tratamento farmacológico , Carcinoma Ductal de Mama/patologia , Carcinoma Ductal de Mama/cirurgia , Carcinoma Lobular/química , Carcinoma Lobular/diagnóstico por imagem , Carcinoma Lobular/tratamento farmacológico , Carcinoma Lobular/patologia , Carcinoma Lobular/cirurgia , Quimioterapia Adjuvante , Estrogênios , Feminino , Humanos , Antígeno Ki-67/análise , Metástase Linfática , Pessoa de Meia-Idade , Terapia Neoadjuvante , Gradação de Tumores , Neoplasias Hormônio-Dependentes/química , Neoplasias Hormônio-Dependentes/diagnóstico por imagem , Neoplasias Hormônio-Dependentes/tratamento farmacológico , Neoplasias Hormônio-Dependentes/patologia , Neoplasias Hormônio-Dependentes/cirurgia , Progesterona , Prognóstico , Estudos Prospectivos , Receptor ErbB-2/análise , Receptores de Estrogênio/análise , Receptores de Progesterona/análise , Carga Tumoral
3.
Acta Otorrinolaringol Esp ; 50(4): 336-40, 1999 May.
Artigo em Espanhol | MEDLINE | ID: mdl-10431087

RESUMO

Adenoid cystic carcinomas are malignant epithelial tumors that originate in body regions containing exocrine and eccrine glands. Their most common location is the salivary glands. These tumors have specific, highly individualized histopathological and clinical features. Three cases of adenoid cystic carcinoma in different sites, palate, sublingual gland, and nasal cavity, are reported. The literature is reviewed for information about the fundamental clinical, diagnostic, and therapeutic aspects of these tumors.


Assuntos
Carcinoma Adenoide Cístico/diagnóstico , Neoplasias Bucais/diagnóstico , Palato/diagnóstico por imagem , Palato/patologia , Neoplasias dos Seios Paranasais/diagnóstico , Neoplasias da Glândula Sublingual/diagnóstico , Idoso , Carcinoma Adenoide Cístico/terapia , Terapia Combinada , Feminino , Humanos , Masculino , Neoplasias Bucais/terapia , Palato/efeitos da radiação , Palato/cirurgia , Neoplasias dos Seios Paranasais/terapia , Radiografia , Neoplasias da Glândula Sublingual/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA